GH Research (NasdaqGM:GHRS) is back in focus after reporting positive Phase 2b data for its inhaled mebufotenin candidate GH001 in treatment resistant depression, with rapid, placebo adjusted improvements maintained over six months.

The recent clinical update has arrived alongside a strong run in the stock, with a 30 day share price return of 16.73% and a year to date share price return of 67.07%. The 1 year total shareholder return of 98.03% points to building momentum around the $22.12 share price.

If this kind of clinically driven move has your attention, it could be a good moment to see what else is setting up in healthcare related AI, starting with 34 healthcare AI stocks.

With GH Research still loss making and now armed with fresh Phase 2b data plus a shelf and at the market program, the key question is simple: is GHRS undervalued at about $22 or already pricing in future growth?

Preferred Price to Book Multiple of 5.8x: Is it justified?

On a simple yardstick, GH Research trades on a P/B of 5.8x at a last close of $22.12. This sits well above both peers and the broader US pharmaceuticals industry.

P/B compares the market value of the equity with the book value on the balance sheet. It is often used for companies without meaningful revenue or earnings. For GH Research, which reported no revenue and a loss of $56.413m, this places almost all of the focus on the value investors assign to its pipeline and clinical progress rather than current cash generation.

Relative to the US pharmaceuticals industry P/B of 2.3x and a peer average of 3.4x, the 5.8x multiple appears elevated and indicates that the market is paying a premium for GH Research’s assets and development outlook compared with many similar companies.

Result: Price-to-book of 5.8x (OVERVALUED).

However, fresh Phase 2b data and a premium 5.8x P/B also raise clear risks, including future funding needs and clinical or regulatory setbacks that could quickly reset expectations.

Next Steps

With sentiment clearly leaning toward optimism, this is a moment to move quickly, check the data yourself and weigh those concerns, starting with 2 important warning signs.

Looking for more investment ideas?

If GH Research is on your radar, do not stop here. Use this moment to broaden your watchlist and line up your next potential opportunities.

• Spot potential mispricings early by scanning 49 high quality undervalued stocks that combine solid fundamentals with attractive valuation signals.
• Strengthen your income focus by reviewing 10 dividend fortresses that pair 5%+ yields with an emphasis on resilience.
• Prioritise stability by checking 66 resilient stocks with low risk scores designed to highlight companies with lower risk profiles and more robust balance sheets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.